{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T02:43:11Z","timestamp":1784083391237,"version":"3.55.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cardiacep.theclinics.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiac Electrophysiology Clinics"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ccep.2022.05.006","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T21:23:58Z","timestamp":1661376238000},"page":"533-545","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antiarrhythmic Drug Therapy in the Treatment of Acute and Chronic Atrial Flutter"],"prefix":"10.1016","volume":"14","author":[{"given":"Martina","family":"Amadori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rapacciuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Diemberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccep.2022.05.006_bib1","series-title":"Cardiac arrhythmia: mechanisms, diagnosis and management","first-page":"501","article-title":"Atrial flutter","author":"Waldo","year":"2001"},{"key":"10.1016\/j.ccep.2022.05.006_bib2","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1046\/j.1540-8167.2001.00852.x","volume":"12","author":"Saoudi","year":"2001","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.ccep.2022.05.006_bib3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0008-6363(01)00549-1","article-title":"Mechanisms of atrial flutter and atrial fibrillation: distinct entities or two sides of a coin?","volume":"54","author":"Waldo","year":"2002","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ccep.2022.05.006_bib4","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1161\/01.CIR.103.7.1025","article-title":"Role of functional block extension in lesion-related atrial flutter","volume":"103","author":"Tomita","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ccep.2022.05.006_bib5","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S0735-1097(86)80429-6","article-title":"A\u00a0new animal model of atrial flutter","volume":"8","author":"Page","year":"1986","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccep.2022.05.006_bib6","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0022-5223(19)36723-6","article-title":"The surgical treatment of atrial fibrillation. II. Intraoperative electrophysiologic mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation","volume":"101","author":"Cox","year":"1991","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ccep.2022.05.006_bib7","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jacc.2020.05.062","article-title":"Comparison of atrial remodeling caused by sustained atrial flutter versus atrial fibrillation","volume":"76","author":"Guichard","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccep.2022.05.006_bib8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0002-9149(96)00560-7","article-title":"Electrophysiology and pharmacology of ibutilide","volume":"78","author":"Naccarelli","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ccep.2022.05.006_bib9","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/eurheartj\/ehz467","article-title":"2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC)","volume":"41","author":"Brugada","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ccep.2022.05.006_bib10","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jacc.2015.09.019","volume":"67","author":"Page","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccep.2022.05.006_bib11","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1053\/euhj.1998.1220","article-title":"Genetic and molecular basis of cardiac arrhythmias; impact on clinical management. Study group on molecular basis of arrhythmias of the working group on arrhythmias of the european society of cardiology","volume":"20","author":"Priori","year":"1999","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ccep.2022.05.006_bib12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.phrs.2019.04.028","article-title":"Quinidine-A legacy within the modern era of antiarrhythmic therapy","volume":"144","author":"Vitali Serdoz","year":"2019","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ccep.2022.05.006_bib13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2165\/00002512-199813010-00006","article-title":"Clinical pharmacology of antiarrhythmic drugs","volume":"13","author":"Capucci","year":"1998","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ccep.2022.05.006_bib14","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0735-1097(95)00459-9","article-title":"Pharmacologic alterations in human type I atrial flutter cycle length and monophasic action potential duration. Evidence of a fully excitable gap in the reentrant circuit","volume":"27","author":"Stambler","year":"1996","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccep.2022.05.006_bib15","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1136\/hrt.44.3.240","article-title":"Response of atrial flutter to overdrive atrial pacing and intravenous disopyramide phosphate, singly and in combination","volume":"44","author":"Camm","year":"1980","journal-title":"Br Heart J"},{"key":"10.1016\/j.ccep.2022.05.006_bib16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0002-9149(85)90591-0","article-title":"Antiarrhythmic drug classification: new science and practical applications","volume":"56","author":"Harrison","year":"1985","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ccep.2022.05.006_bib17","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/00005344-199504000-00005","article-title":"Acute intravenous conversion of canine atrial flutter: comparison of antiarrhythmic agents","volume":"25","author":"Buchanan","year":"1995","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.ccep.2022.05.006_bib18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1161\/01.CIR.74.1.197","article-title":"Pharmacologic conversion and suppression of experimental canine atrial flutter: differing effects of d-sotalol, quinidine, and lidocaine and significance of changes in refractoriness and conduction","volume":"74","author":"Feld","year":"1986","journal-title":"Circulation"},{"key":"10.1016\/j.ccep.2022.05.006_bib19","first-page":"1","article-title":"Mexiletine for ventricular arrhythmias in patients with chronic coronary syndrome: a cohort study","author":"Mugnai","year":"2021","journal-title":"Acta Cardiol"},{"key":"10.1016\/j.ccep.2022.05.006_bib20","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.5603\/KP.2017.0189","article-title":"Efficacy and tolerability of mexiletine treatment in patients with recurrent ventricular tachyarrhythmias and implantable cardioverter-defibrillator shocks","volume":"75","author":"Sobiech","year":"2017","journal-title":"Kardiol Pol"},{"key":"10.1016\/j.ccep.2022.05.006_bib21","first-page":"211","article-title":"Flecainide acetate: concentration-response relationships for antiarrhythmic and electrocardiographic effects","volume":"13","author":"Boriani","year":"1993","journal-title":"Int J Clin Pharmacol Res"},{"key":"10.1016\/j.ccep.2022.05.006_bib22","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/cvr\/26.11.1121","article-title":"Differential block of cardiac delayed rectifier current by class Ic antiarrhythmic drugs: evidence for open channel block and unblock","volume":"26","author":"Follmer","year":"1992","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ccep.2022.05.006_bib23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ccep.2022.05.006_bib24","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1056\/NEJMoa041233","article-title":"Outpatient treatment of recent-onset atrial fibrillation with the \"pill-in-the-pocket\" approach","volume":"351","author":"Alboni","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2022.05.006_bib25","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.2165\/00003495-200464240-00003","article-title":"Pharmacological cardioversion of atrial fibrillation: current management and treatment options","volume":"64","author":"Boriani","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.ccep.2022.05.006_bib26","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/cvr\/25.3.223","article-title":"Antiarrhythmic drugs preferentially produce conduction block at the area of slow conduction in the re-entrant circuit of canine atrial flutter: comparative study of disopyramide, flecainide, and E-4031","volume":"25","author":"Inoue","year":"1991","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ccep.2022.05.006_bib27","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/0735-1097(91)90773-3","article-title":"Effects of antiarrhythmic drugs on canine atrial flutter due to reentry: role of prolongation of refractory period and depression of conduction to excitable gap","volume":"18","author":"Inoue","year":"1991","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccep.2022.05.006_bib28","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/oxfordjournals.eurheartj.a060402","article-title":"Atrial flutter can be terminated by a class III antiarrhythmic drug but not by a class IC drug","volume":"15","author":"Crijns","year":"1994","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ccep.2022.05.006_bib29","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/0735-1097(90)90326-K","article-title":"The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm","volume":"16","author":"Suttorp","year":"1990","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccep.2022.05.006_bib30","first-page":"117","article-title":"Intravenous sotalol for conversion of atrial flutter in infants","volume":"4","author":"Aljohani","year":"2018","journal-title":"Heart Rhythm Case Rep"},{"key":"10.1016\/j.ccep.2022.05.006_bib31","first-page":"1","article-title":"Favourable outcome for hydrops or cardiac failure associated with fetal tachyarrhythmia: a 20-year review","author":"Tunca Sahin","year":"2021","journal-title":"Cardiol Young"},{"issue":"Suppl C","key":"10.1016\/j.ccep.2022.05.006_bib32","doi-asserted-by":"crossref","first-page":"C27","DOI":"10.1093\/eurheartj\/18.suppl_C.27","article-title":"Using the right drug: a treatment algorithm for regular supraventricular tachycardias","volume":"18","author":"Levy","year":"1997","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ccep.2022.05.006_bib33","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1161\/CIRCULATIONAHA.106.638395","article-title":"Results from the Loire-Ardeche-Drome-Isere-Puy-de-Dome (LADIP) trial on atrial flutter, a multicentric prospective randomized study comparing amiodarone and radiofrequency ablation after the first episode of symptomatic atrial flutter","volume":"114","author":"Da Costa","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ccep.2022.05.006_bib34","doi-asserted-by":"crossref","first-page":"944","DOI":"10.2174\/1381612822666161006141512","article-title":"Outcomes with dronedarone in atrial fibrillation: what differences between Real-world practice and trials? A meta-analysis and meta-Regression analysis","volume":"23","author":"Diemberger","year":"2017","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ccep.2022.05.006_bib35","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1540-8167.2010.01764.x","article-title":"A\u00a0short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study","volume":"21","author":"Le Heuzey","year":"2010","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.ccep.2022.05.006_bib36","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/ehjcvp\/pvaa018","article-title":"Comparison of dronedarone vs. flecainide in the maintenance of sinus rhythm, following electrocardioversion in adults with persistent atrial fibrillation: a systematic review and meta-analysis","volume":"7","author":"Wilson","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.ccep.2022.05.006_bib37","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1056\/NEJMoa041705","article-title":"Amiodarone versus sotalol for atrial fibrillation","volume":"352","author":"Singh","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2022.05.006_bib38","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1161\/01.RES.65.6.1565","article-title":"Mechanisms of termination of reentrant atrial arrhythmias by class I and class III antiarrhythmic agents","volume":"65","author":"Spinelli","year":"1989","journal-title":"Circ Res"},{"key":"10.1016\/j.ccep.2022.05.006_bib39","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1540-8167.1993.tb01230.x","article-title":"Activation mapping of reentry around an anatomical barrier in the canine atrium: observations during the action of the class III agent, d-sotalol","volume":"4","author":"Boyden","year":"1993","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.ccep.2022.05.006_bib40","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/0002-8703(95)90324-0","article-title":"Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Sotalol Multicenter Study Group","volume":"129","author":"Sung","year":"1995","journal-title":"Am Heart J"},{"key":"10.1016\/j.ccep.2022.05.006_bib41","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1136\/hrt.79.6.568","article-title":"Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide\/Sotalol Comparator Study Group","volume":"79","author":"Vos","year":"1998","journal-title":"Heart"},{"key":"10.1016\/j.ccep.2022.05.006_bib42","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0002-9149(99)00275-1","article-title":"Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and\/or atrial flutter. d,l-Sotalol Atrial Fibrillation\/Flutter Study Group","volume":"84","author":"Benditt","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ccep.2022.05.006_bib43","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.hrthm.2020.01.022","article-title":"Adverse event rate during inpatient sotalol initiation for the management of supraventricular and ventricular tachycardia in the pediatric and young adult population","volume":"17","author":"Chandler","year":"2020","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.ccep.2022.05.006_bib44","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1517\/13543784.14.5.655","article-title":"Ibutilide--recent molecular insights and accumulating evidence for use in atrial flutter and fibrillation","volume":"14","author":"Doggrell","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ccep.2022.05.006_bib45","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1540-8167.1996.tb00506.x","article-title":"Antiarrhythmic and electrophysiologic effects of intravenous ibutilide and sotalol in the canine sterile pericarditis model","volume":"7","author":"Buchanan","year":"1996","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.ccep.2022.05.006_bib46","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00005344-199307000-00002","article-title":"Antiarrhythmic and electrophysiologic effects of ibutilide in a chronic canine model of atrial flutter","volume":"22","author":"Buchanan","year":"1993","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.ccep.2022.05.006_bib47","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/0735-1097(96)00121-0","article-title":"Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study","volume":"28","author":"Ellenbogen","year":"1996","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccep.2022.05.006_bib48","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ijcard.2006.07.017","article-title":"Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter","volume":"118","author":"Kafkas","year":"2007","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ccep.2022.05.006_bib49","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10557-005-6898-y","article-title":"Clinical comparison of ibutilide and propafenone for converting atrial flutter","volume":"19","author":"Sun","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.ccep.2022.05.006_bib50","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1161\/01.CIR.96.12.4298","article-title":"Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy","volume":"96","author":"Stambler","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.ccep.2022.05.006_bib51","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.eupc.2004.03.007","article-title":"Efficacy and safety of ibutilide vs. transoesophageal atrial pacing for the termination of type I atrial flutter","volume":"6","author":"Mazza","year":"2004","journal-title":"Europace"},{"key":"10.1016\/j.ccep.2022.05.006_bib52","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1592\/phco.23.3.296.32109","article-title":"Effects of intravenous magnesium sulfate on the QT interval in patients receiving ibutilide","volume":"23","author":"Caron","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ccep.2022.05.006_bib53","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.amjcard.2010.04.020","article-title":"Effect of high doses of magnesium on converting ibutilide to a safe and more effective agent","volume":"106","author":"Patsilinakos","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ccep.2022.05.006_bib54","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ccep.2016.02.006","article-title":"Dofetilide: electrophysiologic effect, efficacy, and safety in patients with cardiac arrhythmias","volume":"8","author":"Shenasa","year":"2016","journal-title":"Card Electrophysiol Clin"},{"key":"10.1016\/j.ccep.2022.05.006_bib55","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0735-1097(96)00506-2","article-title":"Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators","volume":"29","author":"Falk","year":"1997","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccep.2022.05.006_bib56","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S0002-8703(99)70363-7","article-title":"Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group","volume":"137","author":"Norgaard","year":"1999","journal-title":"Am Heart J"},{"key":"10.1016\/j.ccep.2022.05.006_bib57","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/0002-9149(92)90247-V","article-title":"Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter","volume":"69","author":"Suttorp","year":"1992","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ccep.2022.05.006_bib58","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10840-008-9290-6","article-title":"Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter","volume":"23","author":"Banchs","year":"2008","journal-title":"J\u00a0Interv Card Electrophysiol"},{"key":"10.1016\/j.ccep.2022.05.006_bib59","series-title":"Dofetilide","author":"Ibrahim","year":"2022"},{"key":"10.1016\/j.ccep.2022.05.006_bib60","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/europace\/eur416","article-title":"Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial","volume":"14","author":"Camm","year":"2012","journal-title":"Europace"},{"key":"10.1016\/j.ccep.2022.05.006_bib61","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/jce.13233","article-title":"Use of adenosine to shorten the post ablation waiting period for cavotricuspid isthmus-dependent atrial flutter","volume":"28","author":"Morales","year":"2017","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.ccep.2022.05.006_bib62","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s43678-021-00167-y","article-title":"2021 CAEP acute atrial fibrillation\/flutter best practices checklist","volume":"23","author":"Stiell","year":"2021","journal-title":"CJEM"},{"key":"10.1016\/j.ccep.2022.05.006_bib63","first-page":"3842","article-title":"Revisiting an underrecognized strategy for rhythm management: hybrid therapy for patients who convert from atrial fibrillation to flutter on antiarrhythmic drugs","volume":"10","author":"Riad","year":"2019","journal-title":"J\u00a0Innov Card Rhythm Manag"}],"container-title":["Cardiac Electrophysiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877918222000363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877918222000363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T05:42:27Z","timestamp":1761802947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877918222000363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1877918222000363"],"URL":"https:\/\/doi.org\/10.1016\/j.ccep.2022.05.006","relation":{},"ISSN":["1877-9182"],"issn-type":[{"value":"1877-9182","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiarrhythmic Drug Therapy in the Treatment of Acute and Chronic Atrial Flutter","name":"articletitle","label":"Article Title"},{"value":"Cardiac Electrophysiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccep.2022.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}